Mevociclib

• CAT Number: I018982
• CAS Number: 1816989-16-8
• Molecular Formula: C₃₁H₃₅ClN₈O₂
• Molecular Weight: 587.12
• Purity: ≥95%
• Storage: Store at -20°C
• IUPAC Name: N-[(1S,3R)-3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]-1-methylcyclohexyl]-5-[[(E)-4-(dimethylamino)but-2-enoyl]amino]pyridine-2-carboxamide
• InChI: InChI=1S/C31H35ClN8O2/c1-31(39-29(42)26-13-12-21(17-33-26)36-27(41)11-7-15-40(2)3)14-6-8-20(16-31)37-30-35-19-24(32)28(38-30)23-18-34-25-10-5-4-9-22(23)25/h4-5,7,9-13,17-20,34H,6,8,14-16H2,1-3H3,(H,36,41)(H,39,42)(H,35,37,38)/b11-7+/t20-,31+/m1/s1
• InChIKey: SCJNYBYSTCRPAO-LXBQGUBHSA-N
• SMILES: CC1(CCCC(C1)NC2=NC=C(C(=N2)C3=CNC4=CC=CC=C43)Cl)NC(=O)C5=NC=C(C=C5)NC(=O)C=CCN(C)C

Mevociclib (Cat No.:I018982) is a highly effective and selective CDK7 inhibitor, with a Ki value of 17.4 nM. This first-in-class compound can induce anti-proliferative and apoptotic effects in cell lines of solid tumors. Mevociclib has shown potential in treating hematological malignancies as well as various aggressive forms of solid tumors, demonstrating significant anti-tumor activity.

Reference

[1]. Hu S, et al. Discovery and characterization of SY-1365, a selective, covalent inhibitor of CDK7. Cancer Res. 2019 May 7.[2]. Shanhu Hu, et al. SY-1365, a potent and selective CDK7 inhibitor, exhibits promising anti-tumor activity in multiple preclinical models of aggressive solid tumors.